Skip to main content
Equibles
ICCC logo

ICCC · Immucell Corp · Investor Relations

Track ICCC — free

Use ICCC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICCC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.80 -0.15 (-1.51%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$90.37M
Shares
9.08M
Volume · Nov 6 8244 Avg daily vol (3M) 16.72K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-13 14:00 UTC Third Quarter Fiscal Year 2026 Conference Call Friday, November 13, 2026 at 9:00 AM ET Earnings Webcast Past Conference Calls Earnings call

Recent news

Date Headline
2026-10-13 ImmuCell ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results
2026-08-13 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
2026-07-09 ImmuCell ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
2026-05-14 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
2026-04-14 ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
2026-04-08 ImmuCell ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
2026-03-04 ImmuCell ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
2026-01-08 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
2025-12-29 ImmuCell ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
2025-11-13 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

Past events

Date Event Type
2026-08-14 Q2 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-05-15 Q1 FY2026 Earnings conference call (announced in 8-K) Earnings call
2026-03-05 Earnings conference call (announced in 8-K) Earnings call
2026-02-26 Earnings conference call (announced in 8-K) Earnings call

Source: https://www.immucell.com/investors

Key facts CIK 811641 CUSIP 452525306 13F (30d) 16 filings 9 filers Visit website Investor relations